First RNA therapy success: man with rare ALS improves after mutation-targeting treatment
burny_tech · x · 2026-09-21
Nature reports that a man with a rare mutation-driven form of motor neuron disease (ALS) became the first person to receive an antisense oligonucleotide therapy targeting his specific genetic mutation. A year later his symptoms improved and he continues working as a physician. Unlike conventional gene therapy, the RNA-based drug acts on the disease-causing transcript. Researchers call the early results exciting, laying groundwork for treating other rare-mutation neurodegenerative diseases.
More from Research
- minpts-check: one-run predictor tells if your HDBSCAN clusters survive min_samples changes — leland_mcinnes · 2026-11-12
- Architecture study sparks monitoring concerns over a multi-hop planning spike — ChowdhuryNeil · 2026-11-12
- SGLang Megakernel Pushes Muse Spark to 1,109 tok/s, 2.1x Over Baseline — hsu_byron · 2026-11-12
- ArcGrav: a cross-model Agent Control Language to cut token overhead — ArchitecturalGravity · 2026-11-12
- Open-source dual-arm robot solves tangram puzzles with 90 demos, ~60% success — DanGrover · 2026-11-12
- FutureHouse's deslopper trains Kosmos to write indistinguishably from human experts — proteinrosh · 2026-11-12